BACKGROUND: For many chemotherapy regimens dosed based on body surface area (BSA), patients experience dose reductions or delays or discontinue treatment, thereby reducing survival. Consideration of body composition may be useful in individualizing chemotherapy dosing, but to the authors' knowledge few studies to date have examined the association of body composition with chemotherapy tolerance in patients with colon cancer. METHODS: The authors identified patients with nonmetastatic colon cancer who were diagnosed from 2006 through 2011 at Kaiser Permanente and who received leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX) as initial adjuvant chemotherapy (533 patients). Patients' muscle mass was quantified using clinically acquired computed tomography scans. The authors quantified chemotherapy doses, treatment dates, and related toxicities using the electronic medical record. In logistic regression models adjusting for age, sex, and American Joint Committee on Cancer stage of disease, the authors examined associations of muscle tertiles with early treatment discontinuation (<6 cycles), treatment delay (>3 days off schedule for 3 times), and/or dose reduction (relative dose intensity 0.70, based on planned treatment). RESULTS: The average age of the patients at the time of diagnosis was 58.7 years; BSA was 1.9 m 2 and body mass index was 28.7 kg/m 2 . Compared with the highest sex-specific tertile of muscle mass, patients in the lowest tertile were more likely to experience toxicities and had twice the risk of adverse outcomes while receiving FOLFOX; for early discontinuation, the odds ratio (OR) was 2.34 (95% confidence interval [95% CI], 1.04-5.24; P for trend 5 .03), whereas the ORs were 2.24 (95% CI, 1.37-3.66; P for trend 5 .002) for treatment delay and 2.28 (95% CI, 1.19-4.36; P for trend 5 .01) for dose reduction. CONCLUSIONS: Lower muscle mass is associated with greater toxicity and poor chemotherapy adherence among patients receiving FOLFOX. Many chemotherapy drugs are dosed based on BSA, but treatment may be better individualized if muscle mass is considered.
INTRODUCTION
There is great heterogeneity in patients' tolerance for cancer treatment that is not explained by age, comorbidities, or other information collected as part of routine clinical care. 1, 2 Many chemotherapy treatments are dosed based on body surface area (BSA), with recommended milligrams (mg) per BSA (m 2 ) derived from trials testing for dose-limiting toxicities. Nevertheless, many patients still experience severe toxicity and subsequently experience reductions in dose or dose delays or discontinue treatment prematurely. Discontinuation, reductions, and delays in chemotherapy can reduce overall and recurrence-free survival, 3 making individualized dosing a priority. Body composition, the amount and distribution of adipose and lean soft tissue (the main compartment of which is skeletal muscle mass), is one factor influencing the pharmacokinetics and metabolism of many chemotherapy agents. Prior research indicates there is substantial variation in body composition among patients with identical BSA 4 ; lower muscle mass may result in a smaller tissue volume for the distribution of certain cancer therapies, with potentially lower capacity for metabolism and clearance of drugs, leading to greater toxicity. This observation has led to the suggestion that body composition should be considered in addition to BSA when dosing chemotherapy. [4] [5] [6] [7] [8] Individualizing chemotherapy based on body composition has yet to be integrated into clinical practice due to a lack of trial evidence and, until recently, a lack of readily available tools such as computed tomography (CT) with which to evaluate and standardize muscle mass measurements in the clinical setting. Existing observational studies of muscle mass and chemotherapy outcomes have been limited by sample size and thus have not adequately accounted for important covariates such as age, stage of disease, race/ethnicity, or comorbidities. This makes it difficult to conclude whether lower muscle mass is an independent predictor of treatment outcomes. 6, 7 Furthermore, previous studies have been conducted primarily among patients with metastatic disease; have not investigated sex differences; and have focused on toxicity without capturing the reductions in chemotherapy adherence due to early discontinuation, treatment delays, or dose modifications that are presumed to be associated with survival.
To the best of our knowledge, the current study is the first to examine whether muscle mass at the time of diagnosis is associated with early discontinuation, treatment delays, or dose reductions of adjuvant chemotherapy independent of demographic and health characteristics. We studied these outcomes among 533 patients with American Joint Committee on Cancer stage II or III colon cancer who were receiving leucovorin calcium/calcium folinate, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) as the first-prescribed adjuvant chemotherapy regimen at Kaiser Permanente Northern California (KPNC). As a secondary objective, we examined sex differences in the associations.
MATERIALS AND METHODS

Study Population
The population of the current study was derived from patients in the "C-SCANS" (Sarcopenia, Colorectal cancer, And Near-term Survival) cohort, which has been described in detail elsewhere. [9] [10] [11] [12] . Muscle mass was quantified from a CT scan obtained before chemotherapy or radiotherapy, if received. The median time from diagnosis to the CT scan was 6 days (range, -2 to 4 months; 79% presurgical). A single trained researcher (J.X.) selected the third lumbar vertebra (L3) and analyzed the cross-sectional area of muscle in centimeters squared (cm 2 ) according to tissuespecific Hounsfield unit ranges using the sliceOmatic software (version 5.0; TomoVision, Magog, Quebec, Canada). 13 Single-slice abdominal cross-sectional areas are reportedly strongly correlated with whole-body volumes of muscle tissue (correlation coefficient, 0.90), 14 and are commonly used to assess body composition in patients with cancer. 15, 16 Figure 1 shows the CT scans of 2 example patients in the current study cohort with the L3 muscle areas analyzed using sliceOmatic software. We categorized muscle cross-sectional area at the L3 into sexspecific tertiles; the highest tertile indicated the greatest muscularity and served as the reference category.
We reviewed the KPNC electronic medical record (EMR) and cancer registry for patient demographics (eg, age, race/ethnicity, and sex) and stage of disease.
Treatment Outcomes
Information regarding adjuvant chemotherapy, including BSA (in m 2 ), treatment dates, and toxicities during treatment, was obtained from the EMR, chemotherapy infusion tables, and laboratory records. The first cycle began with the date of chemotherapy initiation and ended with the date of the next administration (ie, cycle), provided that it was at least 6 days, but 90 days, after the date of the initiation of chemotherapy (median time between cycles was 14 days). The National Comprehensive Cancer Network guidelines recommend 12 cycles of adjuvant FOLFOX for all patients with stage III and high-risk stage II colon cancer. We defined "early discontinuation" as receiving < 6 cycles to capture severe discontinuations likely to influence tumor response. Patients who switched to a regimen that did not include 5-FU and/or oxaliplatin were considered to have discontinued FOLFOX. Because patients often discontinued oxaliplatin before discontinuing 5-FU, we calculated early discontinuation for the regimen at the time that oxaliplatin was discontinued. To distinguish clinically significant treatment delays, we counted each instance over the course of therapy that the patient received chemotherapy 3 days later than the guidelinerecommended 2-week gap between administrations and dichotomized this at 3 instances of treatment delay. As per prior publications, 17 we computed the relative dose intensity (RDI) over the course of therapy actually received as the delivered dose intensity (total dose in mg/ m 2 actually administered divided by the time in weeks to complete chemotherapy) divided by the expected dose intensity based on the planned course of treatment (first administered dose in mg/m 2 divided by 24 weeks, which is the standard time to complete 12 cycles of FOLFOX). We defined "dose reductions" as an RDI < 0.70, which is a standard cutpoint used in the oncology literature. Each chemotherapy treatment outcome was defined separately for 5-FU and oxaliplatin, and averaged to report on outcomes for the regimen.
We defined common toxicities during chemotherapy using laboratory and diagnosis data available in the medical record. These were neutropenia (defined as an absolute neutrophil count <1000/mL or 9) , and thrombocytopenia (defined as a platelet count <50K/mL or ICD-9 codes 287.4 and 287.5).
Statistical Analysis
Time to death as a function of severe early discontinuation (<6 cycles of FOLFOX) was evaluated using KaplanMeier curves and compared with the log-rank test. We present descriptive statistics (means 6 the standard deviations [SD], medians [range], and percentages) overall and by tertile of muscle mass at the time of diagnosis (Table  1) . Separate logistic regression models were fit to estimate the association between tertiles of muscle mass and each dichotomous chemotherapy outcome defined above. All models were adjusted for age, sex, and stage of disease. We further adjusted for BMI category to understand the independent effect of muscle mass; BMI is positively correlated with muscle mass and could have had a nonlinear relationship with chemotherapy outcomes based on the prior literature. [18] [19] [20] [21] When BMI and muscle mass are in the same model, BMI can be understood as controlling for the component of mass uncorrelated with muscle (primarily fat). 22 Race/ethnicity, Charlson Comorbidity Index category (excluding cancer), 23 and year of diagnosis were not found to be associated with chemotherapy outcomes, and adjustment for these variables made little difference to the estimated effect of muscle mass, indicating they were not confounders 24 ; therefore, these variables were excluded from the final models. We calculated the P value for trend by using the ordinal tertile coding continuously (0, 1, and 2) in logistic regression models.
We evaluated differences by sex in stratified analyses and through likelihood ratio tests comparing models with cross-product terms for sex with muscle tertile with models without these terms. In sensitivity analyses, we controlled for BSA instead of BMI category as a covariate, and considered alternate definitions of our outcomes: early discontinuation (3 cycles instead of < 6 cycles), treatment delays (1 instance of a delay instead of 3 instances), and dose reduction (RDI < 0.85 instead of RDI < 0.70). To evaluate whether muscle mass was associated with chemotherapy tolerance independent of more commonly collected biomarkers, we controlled for serum albumin in the subset of 171 participants (32%) with available laboratory values. We further restricted analysis to the 410 participants (77%) who initiated chemotherapy within 60 days of surgery, which is standard in our health system. Table 1 shows descriptive characteristics of the patient population in the current study overall and by sex-specific tertile of muscle mass at the time of diagnosis. The mean age at diagnosis was 58.7 years (SD, 11.28 years), the BSA was ; approximately 45% of patients were male. Patients in the lowest tertile of muscle mass at the time of diagnosis tended to be older, with lower BMI and BSA, and were more likely to report non-Hispanic white or Asian/Pacific Islander race/ethnicity and to experience neutropenia or thrombocytopenia during chemotherapy. Patients in the highest tertile of muscle mass were younger, with higher BMI and BSA, and were more likely to report black/African American race/ethnicity.
RESULTS
There was substantial variation in muscle mass noted among patients with similar BSA. patient B). BSA explained only limited variation in muscle (R 2 , 0.50 in women and R 2 , 0.40 in men). As demonstrated by the Kaplan-Meier curves, patients with severe early discontinuation (<6 cycles of FOLFOX) had shorter survival (log-rank P 5 .04) (Fig. 2) . Exploratory analyses (Table 2) revealed that early discontinuation was most common among patients in the lowest tertile of muscle mass, with 10% of patients completing < 6 cycles of 5-FU and 15% of patients completing < 6 cycles of oxaliplatin, which are nearly twice the rates of early discontinuation in the sample overall. A substantial percentage of patients overall (13% for 5-FU and 15% for oxaliplatin) and in the lowest tertile of muscle mass (19% for both drugs) experienced dose reductions (RDI < 0.70). Table 3 and Figure 3 show the association between sex-specific tertiles of muscle mass and chemotherapy outcomes independent of age, sex, and stage of disease at the time of diagnosis. Compared with the highest tertile, patients in the lowest tertile had higher odds of adverse chemotherapy outcomes while receiving FOLFOX, with odds ratios (OR) for early discontinuation of 2.34 (95% confidence interval [95% CI], 1.04-5.24; P for trend 5 .03) and 2.24 (95% CI, 1.37-3.66; P for trend 5 .002) for treatment delay and 2.28 (95% CI, 1.19-4.36; P for trend 5 .01) for dose reduction. When examined separately, patients in the lowest tertile of muscle mass were found to have twice the odds of early discontinuation or treatment delay for both component drugs (5-FU and oxaliplatin). For dose reductions, the OR for 5-FU was 2.45 (95% CI, 1.25-4.81; P for trend 5 .01) and the OR for oxaliplatin was 1.31 (95% CI, 0.72-2.38; P for trend 5 .39) (Fig. 2) . Adjustment for BMI category strengthened the association between low muscle mass and early discontinuation but slightly attenuated associations with treatment delay and dose reduction (Table 3) .
Supporting Information Table 1 shows the results stratified by sex. There was no clear pattern of sex differences that was consistent across chemotherapy outcomes. Although associations between low muscle mass and early discontinuation and dose reduction appeared stronger in men compared with women, all likelihood ratio tests P values were > .05, and thus these differences may not represent true effect modification by sex.
In sensitivity analyses, we considered controlling for BSA in place of BMI as a covariate, with similar results (see Supporting Information Table 2 ): the association between low muscle mass and dose reduction for 5-FU persisted (OR, 2.52; 95% CI, 1.07-5.96), as did associations between low muscle mass and early discontinuation for both 5-FU and oxaliplatin. Alternate definitions of our main outcomes also did not alter the conclusions, nor did controlling for serum albumin or restricting the analysis to those patients who initiated chemotherapy within 60 days of undergoing surgery.
DISCUSSION
To the best of our knowledge, the current study is the first to examine whether muscle mass at the time of diagnosis predicts chemotherapy outcomes in patients with nonmetastatic colon cancer. The results of the current study demonstrated that lower muscle mass was associated with higher odds of early discontinuation, treatment delay, and dose reductions while receiving FOLFOX independent of age, sex, and stage of disease. The current study findings are consistent with the limited prior literature regarding body composition and dose-limiting toxicities in patients with colon cancer. 5, [25] [26] [27] [28] Although previous studies were suggestive of an association, the majority of these studies did not have a sufficient sample size to control for patient characteristics, and none examined early discontinuation, treatment delays, or dose reductions, which are potentially important outcomes for patient survival. The finding in the current study that lower muscle mass was associated with poor chemotherapy tolerance to FOLFOX raises the possibility that normalizing chemotherapy dosing to muscle mass could optimize treatment to prevent toxicities and improve completion rates. However, randomized trials of dose escalation based on muscle mass would be required to change current practice. These trials currently are being piloted for patients with lung cancer. 29 It is interesting to note that although patients initiated chemotherapy by receiving both oxaliplatin and 5-FU, approximately 27% of patients discontinued oxaliplatin before discontinuing 5-FU; thus, although we observed stronger associations between low muscle mass and chemotherapy dose reductions for 5-FU, this may be because patients remained on 5-FU longer and thus had greater opportunity to experience dose modifications. Another possible explanation for the difference in findings is that 5-FU is hydrophilic. 23 Because the volume of distribution for hydrophilic drugs is highly correlated with lean soft tissue and therefore muscle mass, clearance of 5-FU is expected to decrease with decreasing muscle mass. This would lead to increased exposure and potentially greater toxicity, and therefore to the dose reductions, delays, and discontinuations observed in the current study. 30, 31 This hypothesis is supported by prior research observing that lean body mass is an important determinant of pharmacokinetics 32, 33 and an independent predictor of grade 3 to 4 toxicities in patients with colon cancer who are receiving 5-FU dosed based on BSA. 25, 26 Meanwhile, the pharmacokinetics of lipophilic oxaliplatin may be more dependent on body weight or fat than on muscle 26 because physiologic functions influencing drug metabolism, including liver and renal blood flow and glomerular filtration rate, are altered with body size as well as body composition. 6, 7 Consideration of body composition in addition to BSA may be important for dosing both 5-FU and oxaliplatin, but the compartment of interest (muscle or fat mass) may differ. Body composition will likely inform optimal dose calculations for other chemotherapies as well; for example, for drugs eliminated by the liver, muscle may be particularly useful because hepatic clearance is proportional to lean soft tissue (primarily muscle mass) and greater lean soft tissue is correlated with liver volume and liver blood flow. 34 A potential explanation for the current study finding that low muscle mass was associated with poor chemotherapy outcomes is that severe treatment side effects are more likely, either because patients with low muscle mass are overdosed or because they are more frail or have older functional age, thereby conferring a higher risk of toxicity. Similar to prior research, 5,25-28 we found that a higher percentage of patients in the lowest versus highest tertile of muscle mass experienced neutropenia (55% vs 38%; P 5 .008) and thrombocytopenia (13% vs 5%; P 5 .02). However, the results differed with respect to neuropathy: Ali et al observed that peripheral neuropathy was more common among patients with colon cancer who had low lean body mass. 5 We did not observe this trend (lowest vs highest tertile of muscle mass: 17% vs 27% [P 5 .10]). Potential explanations include our use of EMR codes Once a patient discontinued oxaliplatin, they discontinued the regimen even if they continued to receive 5-fluorouracil. Thus, the results for early discontinuation were identical for the regimen and for oxaliplatin, but differed for 5-fluorouracil. f Treatment delay refers to 3 instances of a delay of 3 days in the administration of chemotherapy from the expected (NCCN guideline) schedule of chemotherapy administration, which indicates the gap between cycles should be 2 weeks. g Dose reduction refers to a relative dose intensity of <0.70 calculated based on the planned course of chemotherapy (ie, based on the first administered dose in mg/m 2 ); the relative dose intensity is calculated over the course of chemotherapy received, without penalizing for early discontinuation or missed cycles.
h Regimen values are the average over both 5-fluorouracil and oxaliplatin.
(which underascertain toxicity compared with clinical trials) and study population, because we included only patients with nonmetastatic disease and a larger percentage of obese patients. This highlights a critical nuance: obese patients have greater body size, greater fat mass, and greater absolute lean mass. Obesity has been associated with higher odds of peripheral neuropathy, a common side effect of oxaliplatin, in patients with colon and breast cancer. 19, 35, 36 Greater vulnerability to neuropathy and lower dosing (obese patients in the current study were found to have lower drug [in mg/cm 2 ] per muscle mass) also are potential explanations for the nonsignificant association of low muscle with dose reductions with oxaliplatin. However, because low muscle mass was associated with early discontinuation and treatment delay regardless of the drug examined, another possibility is that the type of toxicity experienced determines the outcome: peripheral neuropathy experienced during treatment with oxaliplatin could lead to early discontinuation and treatment delay but less often to dose reduction, whereas diarrhea, nausea, and neutropenia occurring while receiving 5-FU might lead to all 3 outcomes.
Due to recognized sex differences in body composition (on average men are more muscular), and the observation that women experience more 5-FU-related toxicity than men, [37] [38] [39] we stratified the current study analyses by sex. Contrary to what others have hypothesized in studies with limited statistical power that could not stratify or adjust for sex, 5 if anything, associations were stronger in men. This could be due to the fact that at a given BSA there is even greater variation in muscle mass among men than among women. However, sex differences depended on which chemotherapy outcome was examined, with no clear pattern observed by sex and no significant interactions with sex. One reason for this could be our use of sexspecific tertiles of muscle mass as a main exposure, which account for the lower muscularity of female patients.
Strengths and Limitations
To the best of our knowledge, the current study is the first to examine whether muscle mass predicts chemotherapy tolerance and adherence in patients with nonmetastatic colon cancer, information that could potentially influence clinical practice through optimized chemotherapy dosing or therapeutic interventions to increase muscle mass. In addition, our use of EMR data allowed us to study these relationships among what we believe to be the largest and most ethnically diverse patient population to date, a population more similar to that observed in general oncology practice than prior studies using clinical trial data.
Important caveats should be noted. Lifestyle factors such as physical activity and dietary intake may influence both muscle mass and chemotherapy tolerance, but information regarding these factors was not available in the EMR. Furthermore, important variables that may mediate the relationship between muscle mass and chemotherapy outcomes, such as Eastern Cooperative Oncology Group performance status, were not available for all participants. EMR infusion records consist only of the actual amount of drug administered on a given treatment date. We defined chemotherapy cycles using gaps between administrations and deviations from dose or schedule by assuming the planned course of therapy was as per the National Comprehensive Cancer Network guidelines. In contrast to a trial, in which dosing, timing, and duration are defined by protocol and toxicities are monitored and extensively documented, with EMR data it is more difficult to determine the planned course of therapy for an individual patient and the reasons for subsequent deviations. Relying on available records with specific use codes also likely underascertained toxicities. To account for the fact that deviations in the chemotherapy schedule might be attributable to many other factors aside from toxicity (eg, scheduling logistics), we categorized these outcomes according to conservative and clinically relevant cutoff values (eg, < 6 cycles for early discontinuation and >3 days off schedule > 3 times before deviations were considered as delays) and considered alternative cutoff values in sensitivity analyses. Nevertheless, the decision to modify 5-FU versus oxaliplatin is often very subjective and provider-dependent. The most likely impact is nondifferential misclassification, particularly for dose reductions, thus attenuating our estimates of the association of low Figure 3 . Odds ratios for adverse outcomes while receiving leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX) among 533 patients in the lowest versus highest tertile of muscle mass. Each symbol on the plot represents a separate odds ratio estimate comparing the lowest with the highest tertile of muscle mass from logistic regression models adjusted for age at diagnosis in years, American Joint Committee on Cancer stage of disease, and sex. muscularity with chemotherapy outcomes and widening the confidence intervals.
Finally, the discussion herein centered on the role of muscle mass in pharmacokinetics, but muscle mass also may be a general indicator of functional age and frailty (perhaps a better indicator of a patient's vulnerability to stresses than chronologic age or comorbidities because muscle mass strongly predicts survival in patients with a variety of cancers). 40, 41 Regardless, the findings of the current study reinforce the belief that body composition may aid in individualizing treatment.
Conclusions
Patients with lower muscle mass at a given body size may have higher effective chemotherapy doses than those with higher muscle mass; if patients cannot tolerate treatmentassociated toxicity, this could lead to early discontinuation, treatment delays, or dose reductions and reduced survival. Conversely, patients with higher muscle mass could be underdosed. Diagnostic CT images provide a readily available tool with which to assess body composition in the clinical setting; the current study results suggest information concerning muscle mass derived from these scans could be useful in individualizing chemotherapy dosing. Furthermore, patients with low muscle mass could be targeted for therapeutic interventions (exercise and nutrition) to prevent further loss of muscle during treatment, which has been associated with reduced survival. 42 The issue of whether altered dosing, resistance training, or other therapies are effective in preventing toxicity among patients with colon cancer remains to be determined, but ongoing trials may provide answers. 43 
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